10.29.14
A new randomized, controlled trial of post-menopausal women demonstrated that a proprietary blend of collagen and calcium, KoACT, was far superior to calcium and vitamin D alone in slowing down the leaching of calcium from bones and rebuilding new bone strength. An abstract of the article was published ahead of print in The Journal of Medicinal Food.
The research was conducted by Bahram H. Arjmandi, PhD, RDN, who is currently Margaret A. Sitton Named Professor and Chair of the Department of Nutrition, Food, and Exercise Sciences at The Florida State University.
Dr. Bahram H. Arjmandi, PhD, RDN, said, "This study is the first long-term clinical trial that directly compare the effects of calcium collagen-chelated product, KoACT, to that of calcium and vitamin D on postmenopausal women. We conclude that supplementation with KoACT may provide protection against bone loss and increased bone turnover for which supplementation of calcium and vitamin D alone could not achieve. Based on our three-month study findings presented last April at Experimental Biology 2014 and those of our recent twelve-month study, it can be suggested that KoACT improves bone health in terms of density and biomarkers of bone turnover."
Jennifer Gu, AIDP's vice president of Research and Development, said, "We know that a large percentage of post-menopausal women are not taking a nutritional supplement for bone health. Those who do normally buy some form of calcium product. Our double-blind, placebo controlled clinical studies on KoACT demonstrate that calcium alone or calcium with vitamin D is not the right answer anymore. Women need to stay up-to-date on the research in order to receive optimal bone health by taking the best product. Our product is the only one on the market that 'mimics Mother Nature,' in slowing bone loss by building new bones and slowing bone resorption, the destruction, disappearance, or dissolution of bones. This scientific breakthrough is very important for women to understand. We hope it will help them make the best choice. According to this science, the optimal choice for bone health is provided by taking supplements containing KoACT."
Thirty-nine women were randomly assigned to one of two groups: 5 g of CC containing 500 mg of elemental calcium and 200 IU vitamin D (1,25-dihydroxyvitamin D3) or control (500 mg of calcium and 200 IU vitamin D) daily for twelve months. Total body, lumbar, and hip BMD were evaluated at baseline, six and twelve months using dual-energy x-ray absorptiometry. Blood was collected at baseline, six and twelve months to assess levels of blood biomarkers of bone turnover. Intent-to-treat analysis was performed using repeated measures analysis of variance pairwise comparisons as well as multivariate analysis to assess time and group interactions. The loss of whole body BMD in women taking CC was substantially lower than that of the control group at twelve months (CC: -1.23% vs. control: -3.75%; P =.044). The CC group had significantly reduced levels of sclerostin and tartrate-resistant acid phosphatase (TRAP5b) (P <.05), and higher bone-specific alkaline phosphatase (BAP)/TRAP5b ratio (P <.05) than control at six months.
For more information: www.aidp.com
The research was conducted by Bahram H. Arjmandi, PhD, RDN, who is currently Margaret A. Sitton Named Professor and Chair of the Department of Nutrition, Food, and Exercise Sciences at The Florida State University.
Dr. Bahram H. Arjmandi, PhD, RDN, said, "This study is the first long-term clinical trial that directly compare the effects of calcium collagen-chelated product, KoACT, to that of calcium and vitamin D on postmenopausal women. We conclude that supplementation with KoACT may provide protection against bone loss and increased bone turnover for which supplementation of calcium and vitamin D alone could not achieve. Based on our three-month study findings presented last April at Experimental Biology 2014 and those of our recent twelve-month study, it can be suggested that KoACT improves bone health in terms of density and biomarkers of bone turnover."
Jennifer Gu, AIDP's vice president of Research and Development, said, "We know that a large percentage of post-menopausal women are not taking a nutritional supplement for bone health. Those who do normally buy some form of calcium product. Our double-blind, placebo controlled clinical studies on KoACT demonstrate that calcium alone or calcium with vitamin D is not the right answer anymore. Women need to stay up-to-date on the research in order to receive optimal bone health by taking the best product. Our product is the only one on the market that 'mimics Mother Nature,' in slowing bone loss by building new bones and slowing bone resorption, the destruction, disappearance, or dissolution of bones. This scientific breakthrough is very important for women to understand. We hope it will help them make the best choice. According to this science, the optimal choice for bone health is provided by taking supplements containing KoACT."
Thirty-nine women were randomly assigned to one of two groups: 5 g of CC containing 500 mg of elemental calcium and 200 IU vitamin D (1,25-dihydroxyvitamin D3) or control (500 mg of calcium and 200 IU vitamin D) daily for twelve months. Total body, lumbar, and hip BMD were evaluated at baseline, six and twelve months using dual-energy x-ray absorptiometry. Blood was collected at baseline, six and twelve months to assess levels of blood biomarkers of bone turnover. Intent-to-treat analysis was performed using repeated measures analysis of variance pairwise comparisons as well as multivariate analysis to assess time and group interactions. The loss of whole body BMD in women taking CC was substantially lower than that of the control group at twelve months (CC: -1.23% vs. control: -3.75%; P =.044). The CC group had significantly reduced levels of sclerostin and tartrate-resistant acid phosphatase (TRAP5b) (P <.05), and higher bone-specific alkaline phosphatase (BAP)/TRAP5b ratio (P <.05) than control at six months.
For more information: www.aidp.com
